-
Product Insights
NewRho Kinase – Drugs In Development, 2024
The Rho Kinase pipeline drugs market research report outlays comprehensive information on the Rho Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Respiratory, Oncology, and Central Nervous System which include indications of Ocular Hypertension, Glaucoma, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Pancreatic Ductal Adenocarcinoma, Unspecified Cancer, Amyotrophic Lateral Sclerosis, and Unspecified...
-
Product Insights
NewRho Associated Protein Kinase 2 – Drugs In Development, 2024
The Rho Associated Protein Kinase 2 pipeline drugs market research report outlays comprehensive information on the Rho Associated Protein Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Respiratory, Gastrointestinal, Oncology, and Central Nervous System which include indications of Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Pancreatic...
-
Product Insights
NewRho Associated Protein Kinase 1 – Drugs In Development, 2024
The Rho Associated Protein Kinase 1 pipeline drugs market research report outlays comprehensive information on the Rho Associated Protein Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Respiratory, Non Malignant Disorders, and Gastrointestinal which include indications of Oncology, Breast Cancer, Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous...
-
Product Insights
NewRho Guanine Nucleotide Exchange Factor – Drugs In Development, 2024
The Rho Guanine Nucleotide Exchange Factor pipeline drugs market research report outlays comprehensive information on the Rho Guanine Nucleotide Exchange Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Ophthalmology, and Hematological Disorders which include indications of Oncology, Melanoma, Autoimmune Disorders, Rheumatoid Arthritis, Age Related Macular Degeneration, and Febrile Neutropenia. It also reviews key players...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Cavernous Hemangioma (Cerebral Cavernous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Pneumoconiosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Pneumoconiosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Pneumoconiosis Drug Details: TDI-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Cavernous Hemangioma (Cerebral Cavernous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vyznova in Corneal Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vyznova in Corneal Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vyznova in Corneal Edema Drug Details: Vyznova a human corneal endothelial...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCU-400 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCU-400 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OCU-400 in Retinitis Pigmentosa (Retinitis) Drug Details: OCU-400 is under...